Clinical Trials Logo

Clinical Trial Summary

This Post Market study is being conducted to compare the direct and indirect cost of three approaches (GFA, myomectomy, and uterine artery embolization) for the treatment of symptomatic uterine fibroids. In addition, data from this study is being used to satisfy the requirements of the United States Food and Drug Administration's 522 (post market surveillance) order.


Clinical Trial Description

The purpose of this study is to 1) evaluate the economic burden, safety and outcomes of three uterine-conserving treatment alternatives for symptomatic uterine fibroids: myomectomy, uterine artery embolization (UAE), and global fibroid ablation (GFA) using the Acessaâ„¢ System, and 2) meet the requirements of the U.S. Food and Drug Administration's 522 Order for post market surveillance In this study, subjects who have symptomatic uterine fibroids will be randomized to one of three uterine-conserving treatments based on the local standard of care. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02163525
Study type Interventional
Source Acessa Health, Inc.
Contact
Status Active, not recruiting
Phase N/A
Start date June 2014
Completion date June 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04960293 - Spherical Gelfoam Versus Tri-acryl Microsphere for Uterine Artery Embolization for Symptomatic Fibroids N/A
Withdrawn NCT01735812 - Laparoscopic Cryoablation of Uterine Fibroids N/A